Pancreatic Cancer Clinical Trial
Official title:
Minimal Access Surgery for Pancreas Cancer: A Phase II Trial Study I: Staging of Pancreas Cancer
RATIONALE: New diagnostic procedures, such as laparoscopic ultrasound, may improve the
ability to detect pancreatic cancer and determine the extent of disease.
PURPOSE: Phase II trial to study the effectiveness of laparoscopic ultrasound in diagnosing
patients with stage I or stage II pancreatic cancer.
OBJECTIVES: I. Determine whether a comprehensive laparoscopic examination of the abdomen
with laparoscopic ultrasonography improves staging of pancreatic cancer with respect to (a)
better assessment (compared to CT) of the extent of localized extra pancreatic disease, (b)
vascular invasion, (c) regional lymph node involvement, and (d) metastatic deposits in liver
parenchyma. II. Assess whether one of the newer minimally invasive imaging techniques,
laparoscopic ultrasonography, predicts vascular invasion in pancreatic cancer. III. Develop
an optimal cost effective strategy for assessing resectability in pancreatic cancer.
OUTLINE: Patients who have undergone routine clinical staging (CT scan, angiogram, etc.) and
who have been classified as potentially resectable undergo laparoscopy and laparoscopic
ultrasound (L+LUS). At the end of the L+LUS, based on the new findings patients are
reclassified as either potentially resectable or potentially unresectable. All patient then
undergo definitive staging: those who have metastasis to the liver that can be
pathologically confirmed by biopsy at the time of the laparoscopy are classified as
unresectable and do not undergo laparotomy; all others undergo laparotomy and then are
classified as resectable or unresectable. If 8 or more patients are misclassified at the
time of the L+LUS, then this study is terminated.
PROJECTED ACCRUAL: There will be 50 patients accrued into this study with 25 patients in
each stage. In order to accrue 50 patients, approximately 70 patients will undergo the
initial routine clinical staging (CT scan, angiogram, etc.).
;
Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|